Celgene is acquiring Juno Therapeutics for $9B, only a few short months after Gilead bought Kite Pharma for $11.9B. The author analyzes the price per share and returns over each of the biotech's funding rounds.
from Forbes Real Time https://www.forbes.com/sites/brucebooth/2018/01/23/two-carts-two-charts-dissecting-returns-from-t-cell-therapy-ma/
via IFTTT
No comments:
Post a Comment